Skip to main content
. 2016 Mar 17;18(5):411–418. doi: 10.1016/j.hpb.2016.02.007

Table 2.

Multivariate model assessing the effect of LRTx in patients with advanced HCC treated with sorafenib

Hazard ratio (95% CI)
ITT analysis (sorafenib vs. sorafenib + LRT) 0.664 (0.544–0.812)
ITT analysis, corrected for imbalances 0.505 (0.407–0.628)
As treated analysis (sorafenib vs. sorafenib + LRT) 0.555 (0.453–0.681)